KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Research & Development: 2012-2024

Historic Research & Development for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $217.5 million.

  • Travere Therapeutics' Research & Development rose 0.41% to $51.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $210.2 million, marking a year-over-year decrease of 2.31%. This contributed to the annual value of $217.5 million for FY2024, which is 11.22% down from last year.
  • Latest data reveals that Travere Therapeutics reported Research & Development of $217.5 million as of FY2024, which was down 11.22% from $245.0 million recorded in FY2023.
  • Over the past 5 years, Travere Therapeutics' Research & Development peaked at $245.0 million during FY2023, and registered a low of $131.8 million during FY2020.
  • In the last 3 years, Travere Therapeutics' Research & Development had a median value of $227.3 million in 2022 and averaged $229.9 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 52.66% in 2021, then fell by 11.22% in 2024.
  • Over the past 5 years, Travere Therapeutics' Research & Development (Yearly) stood at $131.8 million in 2020, then skyrocketed by 52.66% to $201.2 million in 2021, then grew by 13.01% to $227.3 million in 2022, then increased by 7.77% to $245.0 million in 2023, then dropped by 11.22% to $217.5 million in 2024.